CytoMed Therapeutics Limited
As of Oct 22, 2026, CytoMed Therapeutics is in Stage 4, the downtrend phase, now in week 12 (since Aug 4, 2026). It closed at $0.92, 65.7% below its 52-week high and below its 200-day average, which is falling.
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is GDTC early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
GDTC among Biotechnology415th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …415 | GDTC | Stage 4 · wk 12 | 17 | +1.0% |
CytoMed Therapeutics: quick answers
What stage is CytoMed Therapeutics in?
As of Oct 22, 2026, CytoMed Therapeutics (GDTC) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 4, 2026 and is in week 12. What the four stages mean
Is CytoMed Therapeutics in an uptrend?
No. CytoMed Therapeutics is in a Stage 4 downtrend. It trades 7.0% below its 200-day average, which is falling.
How far is CytoMed Therapeutics from its 52-week high?
CytoMed Therapeutics closed at $0.92 on Oct 22, 2026, 65.7% below its 52-week high of $2.68. Its 52-week low is $0.72.
How has CytoMed Therapeutics performed over the past year?
As of Oct 22, 2026, CytoMed Therapeutics is down 64.2% over the past year and down 33.9% so far in 2026.
Which sector and industry is CytoMed Therapeutics in?
CytoMed Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.